Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
  • C07D313/02—Seven-membered rings
  • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
  • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
  • C07D313/12—[b,e]-condensed
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/16—Central respiratory analeptics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to a preventive and/or therapeutic agent for sleeping disorder and the like.
• Sleeping disorder is defined as a general term of disorder of falling asleep, disorder of sleeping duration, disorder of hypersomnia, disorders that cause abnormal actions associated with sleeping and the like. For example, sleeplessness, sleep apnea syndrome and daytime hypersomnia caused by sleep apnea syndrome have been known ( Merck Manual, 14th ed., chap. 173, 1999 ).
• Sleeplessness is characterized by conditions such as incapability to fall asleep, difficulty in sleeping continually, incapability to obtain satisfactory sleep due to hindrance of sleeping pattern and the like, and in addition to mental stress, pains and the like, respiration disorder during sleep is said to be one of the causes for sleeplessness ( Merck Manual, 14th ed., chap. 173, 1999 ).
• the sleep apnea syndrome has a basic feature that apnea (condition in which respiration stops for more than 10 seconds) or hypopnea (condition in which a ventilation amount is less than half of the ordinary respiration) occurs intermittently ( Merck Manual 14th ed. chap. 173, 1999 and the like), and because of hypoxemia, hypercapnemia, respiratory acidosis, an awaking reaction and the like which are triggered by apnea or hypopnea, the disease induces various symptoms such as; complications of, for example, hypertension, cerebrovascular accidents and ischemic heart disease; mental disorders; or the like.
• the sleep apnea syndrome occurs most frequently among diseases showing daytime hypersomnia (sleepiness).
• the sleep apnea syndrome has now been defined generally as a syndrome having the symptoms that
• sleep apnea syndrome examples include a syndrome caused by weakening of a respiratory center during sleep because of disorder in the respiratory center (central sleep apnea syndrome: CSAS), a syndrome that triggers airway obstruction by relaxation of an upper respiratory tract muscle during sleep (obstructive sleep apnea syndrome (OSAS)) and a mixed type of both cases (mixed sleep apnea syndrome: MSAS).
• CSAS central sleep apnea syndrome
• OSAS obstructive sleep apnea syndrome
• MSAS mixed type of both cases
• a nasal-continuous positive airway pressure (nasal-CPAP) method has probed to be effective, and it has been recognized as the first choice at present.
• a therapeutic method after this method installation of an oral appliance (OA), an upper respiratory tract surgical operation method and the like are mentioned.
• OA oral appliance
• an effective ratio is said to be about 60 to 70%, and there are many incomplete patients of the same because of pain in jaw or the like.
• the respective therapeutic methods have their own problems. Meanwhile, with respect to drug therapy, no high effectiveness has been currently established.
• dibenzo[b,e]oxepine derivatives or pharmaceutically acceptable salts thereof are known as compounds having, for example, an antiallergic function, an antiinflammatory function, an antiasthmatic function, and the like (refer to Patent Documents 1, 2, 3, 4, 5, and 6, and Non-patent Document 1).
• compound I -11-(3-dimethylaminopropylidene)-6,11-dihydrodibenzo[b,e]oxepine-2-acetic acid
• compound I is known to have a histamine antagonism (refer to Non-patent Documents 2 and 3), an inhibitory action on chemical transmitter liberation (refer to Non-patent Document 4), an inhibitory action on inflammatory cytokine liberation (refer to Non-patent Document 5), an inhibitory action on tachykinin liberation (refer to Non-patent Document 6), and the like, and is clinically used as an antiallergic agent.
• Non-patent Document 7 It has also been found from a Phase III test that compound 1 has the function to highly improve the nasal congestion of allergic rhinitis (refer to Non-patent Document 7). It has been further known from a basic experiment using guinea pigs that compound 1 has an inhibitory action on a nasal congestion reaction in an experimental allergic rhinitis model (refer to Non-patent Document 8).
• An object of the present invention is to provide a preventive and/or therapeutic agent for sleeping disorder and the like, which comprises, as an active ingredient, a dibenzo[b,e]oxepine derivative or a pharmaceutically acceptable salt thereof.
• the present invention relates to the following items (1) to (18):
• the present invention provides a preventive and/or therapeutic agent for sleeping disorder and the like, which comprises, as an active ingredient, a dibenzo[b,e]oxepine derivative or a pharmaceutically acceptable salt thereof.
• lower alkyl in the definition of each group in formula (I) include linear or branched alkyl having 1 to 8 carton atoms, such as methyl, ethyl, propyl, isopropyl butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, and the like.
• Examples of pharmaceutically acceptable salts of compound (I) or compound 1 include pharmaceutically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts, and the like.
• Examples of pharmaceutically acceptable acid addition salts of compound (I) or compound 1 include inorganic acid salts, such as hydrochlorides, sulfates, and phosphates; organic acid salts, such as acetates, maleates, fumarates, tartrates, citrates, and methanesulfonates.
• Examples of pharmaceutically acceptable metal salts include alkali metal salts, such as sodium salts, and potassium salts; alkaline-earth metal salts, such as magnesium salts, and calcium salts; aluminum salts; zinc salts and the like.
• Examples of pharmaceutically acceptable ammonium salts include ammonium salts, tetramethylammonium salts, and the like.
• Examples of pharmaceutically acceptable organic amine addition salts include addition salts of morpholine, piperidine, and the like.
• pharmaceutically acceptable amino acid addition salts include addition salts of lysine, glycine, phenylalanine, aspartic acid, glutamic acid, and the like. Among these salts, monohydrochlorides are more preferred.
• compound (I) and compound 1 can be obtained by the method described in, for example, Japanese Published Examined Patent Application No. 86925/1993 or a similar method thereto.
• the resulting intermediate can be supplied to a subsequent reaction without particular purification.
• the aimed compound of the production method can be isolated and purified by subjecting to a purification method generally used in synthetic organic chemistry, such as filtration, extraction, washing, drying, concentration, recrystallization, and various types of chromatography.
• salt when compound (I) or compound 1 is obtained in the form of a salt, the salt may be purified as it is. Further, when compound (I) or compound 1 is obtained in a free form, compound (I) or compound 1 may be dissolved or suspended in a suitable solvent, followed by addition of an acid or a base to form a salt.
• Compound (I) or compound 1 and pharmaceutically acceptable salts thereof may exist in the form of an adduct with water or any of various solvents.
• the adduct can also be used for the preventive and/or therapeutic agent for sleeping disorder of the present invention.
• Examples of the sleeping disorder to be prevented or treated in the present invention include sleeping disorder comprising one or more disorders selected from disorder of falling asleep, disorder of sleeping duration, disorder of hypersomnia, disorders that cause abnormal actions associated with sleeping and the like [for example, sleeplessness, sleep apnea syndrome and daytime hypersomnia caused by sleep apnea syndrome], symptoms accompanying these (for example, snore, obstruction of an airway system such as a nose, apnea, hypopnea, arousals and daytime sleepiness) and the like.
• Examples of the sleep apnea syndrome include central, obstructive and mixed sleep apnea syndromes and the like which are generally defined as the sleep apnea syndrome.
• the obstructive or mixed sleep apnea syndrome or the disorder caused by airway obstruction which includes the sleeping disorder caused by obstruction of the airway system such as a nose with high arousals index, is preferably prevented and/or treated.
• the sleep apnea syndrome which is not complicated by allergic rhinitis, which is complicated by airway obstruction by relaxation of an upper respiratory tract muscle during sleep because of non-anallergic rhinitis, morphological abnormality such as tonsillar hypertrophy, obesity, polyp or hypertrophy of nose mucosa, and the like are preferably prevented and/or treated.
• the preventive or therapeutic agent for sleeping disorder of the present invention can prevent, improve or treat symptoms associated with sleeping disorder (for example, symptoms which are secondarily triggered, such as daytime somnolence, decrease in intelligence, change in personality, reduction in concentration ability, morning headache, hallucination, automatism, dyspnea and cerebrovascular accidents).
• symptoms associated with sleeping disorder for example, symptoms which are secondarily triggered, such as daytime somnolence, decrease in intelligence, change in personality, reduction in concentration ability, morning headache, hallucination, automatism, dyspnea and cerebrovascular accidents.
• Compound (I), compound 1, or a pharmaceutically acceptable salt thereof can be administered alone but is preferably provided as various general pharmaceutical preparations.
• the pharmaceutical preparations are used for animals and humans.
• a pharmaceutical preparation according to the present invention may comprise, as an active ingredient, compound (I), compound 1 or pharmaceutically acceptable salts thereof alone or as a mixture with any other effective ingredients.
• a pharmaceutical preparation is prepared by mixing the active ingredient with one or more pharmaceutically acceptable carriers and then subjecting the resulting mixture to any method well known in the technical field of pharmaceutics.
• Examples of other effective ingredients to be incorporated in the pharmaceutical preparation according to the present invention include a nasal steroid and the like.
• the administration route it is preferred to select the most effective route of administration.
• the administration route include oral administration and parenteral administration such as hypodermic administration, intravenous administration, intranasal administration, and the like.
• Examples of a dosage form include a tablet, a powder, granules, syrup, an injection, and the like.
• a liquid preparation suitable for oral administration for example, syrup
• a saccharide such as sucrose, sorbit, fructose
• glycol such as polyethylene glycol or propylene glycol
• oil such as sesame oil, olive oil, or soybean oil
• a preservative such as p-hydroxybenzoate
• a flavor such as a strawberry flavor or peppermint and the like.
• a tablet, a powder, granules and the like can be produced by using an excipient such as lactose, glucose, sucrose, or mannitol, a disintegrator such as starch or sodium alginate, a lubricant such as magnesium stearate or talc, a binder such as polyvinyl alcohol, hydroxypropyl cellulose, or gelatin, a surfactant such as a fatty acid ester, a plasticizer such as glycerin, and the like.
• an excipient such as lactose, glucose, sucrose, or mannitol
• a disintegrator such as starch or sodium alginate
• a lubricant such as magnesium stearate or talc
• a binder such as polyvinyl alcohol, hydroxypropyl cellulose, or gelatin
• a surfactant such as a fatty acid ester
• plasticizer such as glycerin, and the like.
• An injection for hypodermic or intravenous administration is prepared as, for example, a solution, a suspension, an emulsion, or a solid injection used by dissolving or suspending in a solvent when used.
• a solution, a suspension, or an emulsion is prepared by dissolving, suspending, or emulsifying compound (I), compound 1, or pharmaceutically acceptable salts thereof in a solvent.
• the solvent include distilled water for injection, physiological saline, a buffer (such as phosphate buffer), vegetable oil, propylene glycol, polyethylene glycol, alcohols such as ethanol, and mixtures thereof.
• Such an injection may further contain a stabilizer, a solubilizing agent (such as glutamic acid, aspartic acid, Polysorbate 80 (trade mark), or the like), a suspending agent, an emulsifier, a soothing agent, a buffer, a preservative, or the like.
• a solubilizing agent such as glutamic acid, aspartic acid, Polysorbate 80 (trade mark), or the like
• a suspending agent such as glutamic acid, aspartic acid, Polysorbate 80 (trade mark), or the like
• an emulsifier such as glutamic acid, aspartic acid, Polysorbate 80 (trade mark), or the like
• a suspending agent such as glutamic acid, aspartic acid, Polysorbate 80 (trade mark), or the like
• an emulsifier such as glutamic acid, aspartic acid, Polysorbate 80 (trade mark), or the like
• a suspending agent such as glutamic acid, aspartic acid, Polysorbate 80 (trade
• An external preparation for intranasal administration is, for example, a liquid for external use and the like.
• Such an external preparation is prepared as a solution, a suspension, an emulsion, or a solid preparation used by dissolving or suspending in a solvent when used or the like.
• a solution, a suspension, or an emulsion can be prepared by dissolving, suspending, or emulsifying compound (I), compound 1 or pharmaceutically acceptable salts thereof in a solvent.
• the solvent include physiological saline, a buffer (such as phosphate buffer), propylene glycol, polyethylene glycol, and the like, or mixtures thereof.
• Such a liquid for external use may further contain a stabilizer, a solubilizing agent (such as glutamic acid or aspartic acid), a suspending agent (such as a polymer imparting viscosity, including Polysorbate 80 (trade mark), carboxymethyl cellulose, polyvinyl alcohol or the like), an emulsifier, a buffer, a preservative, or the like.
• a solubilizing agent such as glutamic acid or aspartic acid
• a suspending agent such as a polymer imparting viscosity, including Polysorbate 80 (trade mark), carboxymethyl cellulose, polyvinyl alcohol or the like
• an emulsifier such as a buffer, a preservative, or the like.
• the doses and frequency of administration of compound (I), compound 1, or pharmaceutically acceptable salts thereof may vary depending on the dosage form, the age and body weight of a patient, the nature or seriousness of a symptom to be treated, and the like.
• oral administration in general, a dose of 0.01 mg to 1 g, preferably 0.05 to 50 mg, is administered to an adult once or several times a day.
• parenteral administration such as intravenous administration, a dose of 0.001 mg to 100 mg, preferably 0.01 mg to 10 mg, is administered to an adult once or several times a day.
• these dosages and frequencies of administration vary with the various conditions described above.
• Olopatadine hydrochloride was orally administered at a dose of 10 mg/day [a 5-mg tablet of Allelock (registered trademark: Kyowa Hakko Kogyo Co., Ltd.) was administered everyday, twice a day, with one tablet for each administration] to three patients (patient Nos. 1 to 3) with sleep apnea syndrome complicated by allergic rhinitis and seven patients (patient Nos. 4 to 10) with sleeping disorder which is not complicated by allergic rhinitis including four patients (patient Nos. 4 to 6 and 8) with sleep apnea syndrome which is not complicated by allergic rhinitis.
• a 5-mg tablet of Allelock registered trademark: Kyowa Hakko Kogyo Co., Ltd.
• an apnea-hypopnea index (AHI), an apnea index (AI) and an arousals index per hour were measured respectively by polysonography (PSG) for each patient. Further, before and after the administration of olopatadine hydrochloride, a test for daytime Epworth sleepness scale was performed according to the following.
• RAST radioallergosorbent test
• 12 types of antigens house dust, Dermatophagoides pteronyssinus, Japanese cedar, Hinoki cypress, Japanese alder, ragweed, mugwort, goldenrod, Cocksfoot (Dactylis glomerata), Candida albicans, mold and animal epithelium.
• the effect of the agent was estimated according to the following standard.
• improved conditions in values of AHI, AI, arousals index and ESS were used for reference.
• Table 1-1 Profiles of patients complicated by allergic rhinitis to whom olopatadine hydrochloride was administered and conditions for administration of olopatadine hydrochloride to the patients are shown in Table 1-1, and profiles of patients uncomplicated by allergic rhinitis to whom olopatadine hydrochloride was administered and conditions for administration of olopatadine hydrochloride to the patients are shown in Table 2-1. Further, the results of the PSG measurement and the ESS test are shown in Tables 1-2 and 2-2 respectively.
• Table 1-1 Profiles of patients complicated by allergic rhinitis and conditions for administration of olopatadine hydrochloride Patient No. Age Sex RAST examination result* Chief complaint Administration schedule of olopatadine hydrochloride Administration period (day) 1 72 female + Snore, apnea Morning and before sleep 342 2 55 female + Snore, apnea Morning and before sleep 160 3 38 male + Snore, apnea, daytime sleepiness Evening and before sleep 177 * +:positive [Table 1-2] Table 1-2: Effect of olopatadine hydrochloride on sleeping disorder Patient No.
• olopatadine hydrochloride improves symptoms of sleeping disorder such as snore, apnea, hypopnea, arousals and daytime sleepiness in the patients with sleep apnea syndrome complicated by allergic rhinitis and has a clinical effect to sleep apnea syndrome complicated by allergic rhinitis.
• Table 2-1 Profiles of patients uncomplicated by allergic rhinitis and conditions for administration of olopatadine hydrochloride Patient No. Age Sex RAST examination result* Chief complaint Administration schedule of olopatadine hydrochloride Administration period (day) 4 20 female - Snore, daytime sleepiness, morning headache Morning and evening 74 5 56 male - Snore, apnea Morning and evening 125 6 66 male - Snore, apnea Morning and evening 124 7 56 female - Snore, apnea, daytime sleepiness Evening and before sleep 106 8 63 male - Snore, apnea Evening and before sleep 96 9 59 male - Snore, daytime sleepiness Evening and before sleep 91 10 48 female - Snore, daytime sleepiness Evening and before sleep 160 * -: negative [Table 2-2] Table 2-2: Effect of olopatadine hydrochloride on sleeping disorder.
• olopatadine hydrochloride improves symptoms of sleeping disorder such as snore, apnea, hypopnea, arousals, daytime sleepiness and morning headache in patients with sleeping disorder which is not complicated by allergic rhinitis and has a clinical effect to sleeping disorder which is not complicated by allergic rhinitis.
• olopatadine hydrochloride improves symptoms of sleeping disorder such as snore, apnea, hypopnea, arousals, daytime sleepiness and morning headache and has the clinical effect against sleeping disorder such as sleep apnea syndrome, regardless of the presence or absence of complication by allergic rhinitis.
• Tablet A tablet having the following composition is prepared by a conventional method.
• Prescription Monohydrochloride of compound 1 5 mg Lactose: 61 mg
• Potato starch 30 mg
• Polyvinyl alcohol 3 mg
• Magnesium stearate 1 mg 100 mg
• Powder A powder having the following composition is prepared by a conventional method.
• Prescription Compound 1 10 mg Lactose: 190 mg 200 mg
• An injection having the following composition is prepared by a conventional method.
• Prescription Compound 1 2 mg Purified soybean oil: 200 mg Purified egg-yolk lecithin: 24 mg Glycerin for injection: 50 mg Distilled water for injection: 1.72 mL 2.00 mL
• Syrup Syrup having the following composition is prepared by a conventional method.
• Prescription Compound 1 300 mg Purified sucrose: 40 g Methyl paraoxybenzoate: 40 mg Ethyl paraoxybenzoate: 10 mg Strawberry flavor: 1 mL Distilled water: proper amount 100.00 mL
• the present invention provides a preventive and/or therapeutic agent for sleeping disorder and the like, which comprises, as an active ingredient, a dibenzo[b,e]oxepine derivative or a pharmaceutically acceptable salt thereof.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Pulmonology (AREA)
• Immunology (AREA)
• Anesthesiology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Otolaryngology (AREA)
• Biomedical Technology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Pyrane Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=35785204

Family Applications (1)

Country Status (7)

Families Citing this family (5)

Family Cites Families (4)

• 2005
  • 2005-07-15 CA CA002573915A patent/CA2573915A1/fr not_active Abandoned
  • 2005-07-15 US US11/570,977 patent/US20080287531A1/en not_active Abandoned
  • 2005-07-15 CN CNA2005800227527A patent/CN1980652A/zh active Pending
  • 2005-07-15 WO PCT/JP2005/013114 patent/WO2006009093A1/fr active Application Filing
  • 2005-07-15 KR KR1020077000999A patent/KR20070032785A/ko not_active Application Discontinuation
  • 2005-07-15 JP JP2006529168A patent/JPWO2006009093A1/ja not_active Withdrawn
  • 2005-07-15 EP EP05766306A patent/EP1769794A1/fr not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events